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ABSTRACT 
OBJECTIVES: This study aimed to investigate the total 
concomitant imaging dose accumulated from different imaging 
modalities during the radiotherapy process. The radiation dose 
resulting from imaging modalities is often neglected because it 
is viewed as too low compared to high levels of radiation dose 
normally prescribed for treatment. With recent advances in high 
dose imaging technology integrated into radiotherapy treatment 
units, there has been a growing concern regarding the imaging 
dose as a result of their increased use.  
DESIGN & METHOD: The study was conducted at the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) and Richards Bay Medical 
Institute (RBMI). Imaging modalities investigated at CMJAH were 
fluoroscopy simulation, Computed Tomography (CT) scanning and 
MV planar imaging. Imaging modalities investigated at RBMI were 
kV Cone Beam CT, CT scanning and kV planar imaging. CT dosimetry 
was performed using a head and body phantom with a pencil 
ionisation chamber. A calibrated parallel plate diagnostic 
ionisation chamber with a 30 × 30 cm2 acrylic phantom was used 
for the fluoroscopy simulator and kV planar imaging dosimetry. 
The total imaging dose was estimated as the sum of dose resulting 
from each modality taking into account the number of times 
imaging was performed, on 20 patients from each institution. 
RESULTS:   
CMJAH: The measured volume Computed Tomography Dose Index 
(CTDIvol) was 17.98 ± 1.54 mGy and 20.26 ± 1.64 mGy for head and 
body scanning protocols respectively. The measured simulator 
Entrance Surface Air Kerma (ESAK) dose from pelvic imaging 
protocol for 20 patients of different sizes ranged from 0.16 ± 
0.01 mGy to 0.32 ± 0.03 mGy for anterior-posterior/posterior-
anterior (AP/PA) projections and 1.49 ± 0.13 mGy to 3.18 ± 0.27 
mGy for lateral projections. The total dose accumulated during 
the complete course of treatment from MV portal imaging ranged 
from 5 cGy to 43 cGy for both AP/PA and lateral projections. The 
average estimated  effective doses to  patients resulting from 
a single planning CT procedure, acquisition of one pair of AP/PA 
and lateral simulation films and one session of 6 MV portal 
imaging verification were 7.57 ± 0.61 mSv, 0.19 ± 0.02 mSv and 
4.80 ± 0.24 mSv respectively. Based on a series of 20 patients, 
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the calculated average effective dose accumulated during a 
complete course of treatment were 7.53 ± 0.61 mSv, 0.37 ± 0.03 
mSv and 15.53 ± 0.78 mSv respectively from each modality 
respectively. The greatest contribution to the patient’s total 
effective dose from imaging alone originated from the planning 
CT scan. However when taking into account the number of imaging 
procedures typically prescribed for each modality, the 6 MV 
portal imaging contributed the highest dose. 
RBMI: The measured CTDIvol was 79.60 ± 6.61 mGy and 33.79 ± 2.80 
mGy for the head and body scanning protocols respectively. For 
kVCBCT, the CTDIvol measured was 5.20 ± 0.43 mGy and 14.40 ± 1.19 
mGy for the head and body scanning protocols respectively. The 
ESAK measured for kV planar imaging of the head was 0.31 ± 0.03 
mGy and 0.12 ± 0.01 mGy for the AP/PA and lateral projections 
respectively. For AP/PA pelvic imaging the ESAK ranged from 0.16 
± 0.01 mGy to 0.33 ± 0.03 mGy for small to extra-large patients. 
For lateral imaging the range was 1.49 ± 0.13 mGy to 3.18 ± 0.27 
mGy from small to extra-large patients respectively. The 
estimated average  effective dose to 20 patients resulting from 
the planning CT, kVCBCT and kV portal imaging procedures during 
the complete course of treatment were approximately 19.96 ± 1.66 
mSv, 11.82 ± 0.98 mSv and 1.49 ± 0.12 mSv respectively. The 
greatest contribution to the total effective dose from imaging 
alone originated from the planning CT scan.  
CONCLUSION: The results indicate that considerable dose could be 
delivered to patients during image guided radiotherapy, 
primarily when imaging procedures are over utilized and not 
optimized, adding more burden of dose to the already high levels 
of dose they receive from their treatment. The dose contribution 
from the planning CT was the highest and is influenced primarily 
by the scan length and the number of examinations. This  can be 
reduced if scans are not acquired beyond the region of interest 
(ROI) required for planning purposes or by adjusting protocols 
to larger slice spacing outside the ROI.  
Inadequate scanning of patients can also add more dose to 
patients if the CT examination is repeated to acquire sufficient 
image information required for radiation therapy planning. 
Modern imaging techniques such as kVCBCT applied during patient 
setup verification, can also add a significant dose when 
prescribed to confirm setup on a daily basis. kV planar imaging 
dose was significantly lower than all other imaging modalities 
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researched in this study. Compared with MV planar imaging, the 
average effective dose to the patient during the complete course 
of treatment from MV portal imaging was 7.95 ± 0.65 mSv whereas 
it was 1.49 ± 0.13 mSv from kV portal imaging. Therefore, if the 
soft tissue image information from MV planar imaging is not 
justified, kV imaging is recommended. On the other hand, single 
exposure MV imaging of static treatment ports could be 
subtracted from the prescribed radiotherapy dose.   
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CHAPTER 1 
 
1. INTRODUCTION 
1.1 Brief history of X-rays and imaging 
X-ray imaging began in late 1895 after X-rays where discovered 
by Dr. Wilhelm Conrad Roentgen1, in Wurzburg, Germany. Roentgen 
was studying the effect of cathode rays on gases using a Crookes 
tube when he noticed that a piece of phosphorus material situated 
some distance away in his laboratory was glowing1. Fascinated by 
what he observed, he went on to study the mysterious rays in 
detail for weeks.  
One of his significant observations was that the unknowns rays 
(X-rays) were able to penetrate some solids better that others 
(i.e. more penetration through soft tissue than bone)1. He 
announced the discovery at the Wurzburg Physical Medical Society 
in early 1896. In 1901, he was awarded the Nobel prize1,2. 
Within a few months after the announcement, X-ray tubes were set 
up to image the public for both medical and entertainment 
purposes, viewed at the time as a new form of photography. The 
medical importance of X-rays for diagnostic purposes was 
evident. Within a few months of their discovery, clinicians 
globally were using X-ray imaging to identify bone fractures2.  
A year later, the ability of X-rays to shrink tumors was 
discovered by a French physician, François-Victor Despeignes3, 
marking the beginning of radiation therapy. During those years, 
the potential health hazards of X-ray exposure were unknown. The 
first dangerous side effects were reported by Dr. W Gage4 late 
in 1896. He found that exposure to X-rays resulted in hair loss, 
reddened skin and skin lesions4. The dangers of exposure to 
ionizing radiation became better understood with time and they 
began to be used for only medical procedures rather than for 
entertainment purposes2. 
A cathode X-ray tube was later invented by William Coolidge2 in 
1913. The invention greatly improved the quality of X-ray 
images. Since then, advancements in X-ray imaging technology 
have been made, like the introduction of X-ray tomography in the 
1940’s. The technique was achieved by rotating an X-ray tube 
around the human body, allowing a tomogram to be obtained. The 
imaging technology was further revolutionized with the 
introduction of computers in the 1970’s, enabling the X-ray 
images to be processed and reconstructed by a computer.  
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Two major advancements of the time were the invention of the 
Computed Tomography (CT) technique by Hounsfield and Cormack5 in 
1971 and the development of a Magnetic Resonance Imaging (MRI) 
technique by Raymond Damadia et al.5 in 1976. Both were 
computerized tomographic techniques that could display cross 
sectional slices of a three dimensional object, but unlike the 
X-ray based CT, MRI does not require ionizing radiation.  
 
Other significant imaging inventions of the time include medical 
ultrasound imaging (technique first used clinically in 70’s and 
discovered in 1955)5 and the gamma camera (in the 1950’s by Hal 
Angerln)6 marking the beginning of Nuclear Medicine. The first 
computerized ‘tomoscanner’ gamma camera was also developed in 
the 1970’s. Imaging technology continues to advance to this day, 
driven by the need to achieve better image quality, improve 
imaging speed and to reduce imaging dose.  
                                           
 
1.2 The need for imaging in radiotherapy 
External beam radiotherapy is one of the most common treatment 
options for various types of cancers7. Radiotherapy is normally 
given over a number of fractions or daily sessions; this allows 
larger radiation doses to be delivered to the tumor and time for 
the repair of normal tissues, which reduces the side effects of 
treatment. The success of external beam radiotherapy primarily 
relies on how accurately the target or tumor within the patient 
is identified, how accurately the external radiation beams are 
directed towards the target and also the uniformity and 
conformity of the radiation dose to the target volume. 
All of these tasks are significantly dependent on the Imaging 
technology being employed. Figure 1.1 indicates the three major 
steps during the modern radiotherapy process7. 
(1) Treatment planning 
(2) Treatment delivery    
(3) Post treatment assessment 
All of these steps involve imaging. Images are required for 
three major reasons:  
(1) Imaging for planning, in which the size, shape and depth 
of the target, and the surrounding normal tissue structures 
are identified using a CT scanner. Other imaging techniques 
like Positron Emission Tomography (PET) scanning or MRI 
scanning are at times used to provide additional information 
in order to more precisely localize the target. 
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(2) Imaging to check and verify the accuracy of patient’s 
positioning and target localization before and during 
treatment.   
(3) To assess the effectiveness of treatment by checking if 
the tumor has been eradicated or has shrunk. 
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Fig. 1. Schematic presentation of the imaging process during 
Radiotherapy. kVCBCT/MVCBCT - Mega-Voltage/kilo-Voltage Cone 
Beam Computed Tomography; EPID - Electronic Portal Imaging 
Device; MRI - Magnetic Resonance Imaging; PET-Positron Emission 
Tomography; OAR - Organs At Risk
 
Daily Treatment delivery 
Patient setup with lasers 
Portal Imaging 
(film/EPID) 
Portal Imaging (EPID) 
- kV  image pair  
- kV-MV image pair 
- MV image pair 
kVCBCT / MVCBCT 
kVCBCT / MVCBCT 
Patient repositioning 
Treatment delivery 
 
 
 
 
Treatment Planning 
Planning CT  
- Fusion  with  MRI or PET 
- Contouring ( Target + OAR ) 
Dose Calculations, optimization and plan 
evaluation 
Treatment outcome evaluation (CT, MRI or PET) 
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1.3 Concerns regarding the imaging dose 
The imaging dose accumulated during the radiotherapy process has 
long been neglected partly because of its low magnitude in 
comparison to the high levels of therapeutic dose prescribed to 
treat patients. Recent advances in radiation treatment delivery 
such as 3D conformal radiation treatment (3DCRT) and intensity 
modulated radiation therapy (IMRT) enables the delivery of 
prescribed radiation doses to the target with great conformity 
and uniformity while minimizing the radiation dose to the 
surrounding normal structures, but this can only be achieved 
with accurate target localization. The need to achieve this 
objective has led to advances in imaging technology, and as a 
result the increased imaging has led to increased imaging dose. 
The primary concern is the induction of secondary cancers, due 
to exposure of normal tissue volumes extending beyond the volume 
of interest during imaging8.  
The reported radiation exposure from all medical procedures in 
the National Council on Radiation Protection and Measurements 
(NCRP) report No 160, of March 2006, was 3 mSv, an increase of 
nearly 500% compared to the reported exposure of 0.34 mSv in the 
NCRP report 93, of the 80’s9,10. 
The comparison of medical exposures to patients reported in NCRP 
reports No 93 and 160 is listed in Table 1. Amongst different 
imaging modalities listed, CT was the largest contributor to the 
overall increase in medical exposures. The technological 
advancement made in the past two decades has made it easier for 
CT technology to be applied in many clinical applications.  
According to the  United Nations Scientific Committee on the 
Effects of Atomic Radiation (UNSCEAR) 2008 report, the CT 
accounts to about 7 % of all  X-ray examinations globally,  
contributing approximately 43 % to the total annual collective 
dose11,12, with  the average effective dose from all radiological 
procedures worldwide increasing from 0.38 mSv to 0.62 mSv in the 
period of 1988-200712.  
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Table 1. Comparison of medical exposure of patients in USA 
between 1980 and 2006 from various medical procedures, 
indicating a very high increase due from CT procedures9,10. 
 
 
1.4 Imaging Scenarios for image guided radiation therapy                                                                                   
(IGRT) 
 
1.4.1 CT-Imaging for planning  
CT imaging is the first step in modern radiotherapy planning 
process whereby images are acquired in the treatment position 
for target definition. The ability of a CT to display three 
dimensional internal structures with good contrast and to 
directly measure electron densities makes it an ideal imaging 
modality specifically for the purpose of organ delineation and 
dose computation13.  
 
 
MODALITY 
NCRP REPORT NO 93 
(EARLY 80’S)  
NCRP REPORT NO 160 
(MARCH 2006) 
CT 3% 49% 
Nuclear Medicine 
26% 26% 
Conventional Fluoroscopy and 
Radiography 68% 11% 
Interventioanl Fluoroscopy 
3% 14% 
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Fig. 2.  A typical CT Simulator used in Radiation Therapy is 
shown. 
 
During imaging for planning, a patient is placed on the couch 
with immobilization devices to minimize the patient’s movement 
during scanning and to ensure reproducibility of the position 
for treatment. The patient is then setup with the region of 
interest to be scanned aligned to the CT lasers, which indicate 
the centre of the CT gantry. Once complete, two lateral and one 
anterior radio-opaque balls are placed on the skin surface in 
alignment with the isocenter of the horizontal and vertical 
plane of the lasers. The three balls provide external markers 
that indicate a known reference point that is used in the 
treatment planning system and the actual treatment machine 
(clinical linear accelerator)13. Once the scan has been 
completed, the patient is marked with permanent tattoos on the 
skin where the balls were placed.
Gantry 
Immobilization devices 
CT couch 
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Fig. 3. Axial CT slice with three opaque balls placed on the 
patient’s skin. 
 
 
1.4.2 Treatment simulation 
  Patient simulation is a process that involves: 
 Determination of beam geometry, tumor volumes, organs at 
risk  and the treatment position of the patient 
 Generation of simulation radiographs or Digitally 
reconstructed radiographs (DRRs) 
 
 
Historically, planar simulator radiographs were obtained from a 
conventional radiotherapy simulator, which is a 
radiography/fluoroscopy system with the ability to mimic most 
of the geometries of isocentric treatment machines.  A typical 
conventional simulator is shown in Fig. 5. 
Radio-opaque 
balls  
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Fig. (4). A Set of digitally reconstructed radiographs (DRR’s), 
anterior-posterior and lateral views respectively, 
reconstructed from a planning CT at RBMI. 
In virtual simulation, simulation images and DRRs are generated 
directly from the planning CT information. 
 
Fig. 5. A typical radiotherapy treatment simulator is shown. A 
Simulator can produce treatment geometries that can be obtained 
on a treatment machine. (Image copied from ref. 14) 
1.4.3 Setup verification 
The precise delivery of the planned radiation treatment is 
dependent on the accuracy of patient treatment position. This 
is achieved by comparing the simulator radiographs or DRRs with 
in-room images acquired before patient treatment. Traditionally 
portal images were generated on films (Port films)13, but with 
recent advances in imaging technology, there  exists a variety      
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of imaging modalities such as EPID- based MV planar imaging, kV 
planar imaging, and kV and MV cone beam computed tomography 
(CBCT)15. CBCT enables direct comparison of CBCT images with the 
planning CT images for internal soft tissue target alignment. 
 
 
Fig. 6. A modern Medical Linear Accelerator with kVCBCT, planar 
kV and MV imaging capabilities is shown. 
 
Some institutions employ imaging modalities like in-room CT. The 
in-room CT provides an added advantage of producing the same 
image quality as the planning CT and also enables soft tissue 
target alignment13,15. 
 
 
 
Gantry 
kV 
source 
kV flat panel 
detector 
MV flat panel 
detector 
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1.5 Research objectives 
A lot of research has been devoted to the assessment of the X-
ray imaging dose from different imaging techniques due to an 
increase in the utilization of X-ray imaging. CBCT dose has been 
assessed by a variety of researchers16-22. Extensive research has 
been conducted in dosimetry in diagnostic radiology and a number 
of guidelines and codes of practice exist for measurement of 
dose in CT and other diagnostic X-ray imaging modalities23-28. 
Though measurement and evaluation methods exist for assessment 
of imaging dose from a variety of imaging modalities, little 
effort has been devoted to the measurement and evaluation of the 
total imaging dose from all imaging modalities used for patient 
imaging during the radiotherapy process. 
The American Association of Physicist in Medicine (AAPM) task 
group (TG) 7515, issued a report on management of imaging dose 
during IGRT, with guidelines outlining how to evaluate and 
measure the imaging dose. This Study aims to adopt the same 
methodologies used in the report to measure, evaluate and 
compare the total imaging dose and the resulting effective dose 
received by patients during typical radiotherapy processes from 
different imaging modalities at 2 different centres. 
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CHAPTER 2 
 
2. BACKGROUND 
2.1 Computed Tomography  
During the early days of CT, it became evident that the dose 
concepts applicable to projection radiography could not be used 
to CT for a variety of reasons29,  
 The CT dose distribution is different from that of a 
conventional radiogram, in the sense that in CT, the 
patient is homogeneously irradiated along the scanning 
direction. 
 The CT radiation beams are narrow shaped fan-beams, this 
implies that there is a significant amount of energy 
deposition outside the nominal beam width.  
 
 
 
2.1.1 The CT dose index 
 
The first dose descriptor and a standard for determination of 
radiation dose in a fan beam CT was the multiple scan average 
dose (MSAD)29. The MSAD is defined as the dose from multiple scan 
examinations, averaged over one scan interval along the 
longitudinal scan axis29. It is typically presented in dose unit 
of mGy. 
The process of determining the MSAD was intensive and time 
consuming as it required the acquisition of multiple axial CT 
scans and additional time to allow the X-ray tube to cool down 
in between measurements. This led to the development of computed 
tomography dose index (CTDI).  The CTDI concept was first 
introduced by Shope et al.26 in 1981, defined as the integral of 
the single scan radiation dose profile along the scan 
longitudinal axis, normalized to the thickness of the imaged 
section26. They proved that CTDI can be used to estimate the MSAD 
by applying the correction for scan spacing or pitch, allowing 
all of the scatter tails from radiation dose profiles to be 
included in the CTDI measurement. The CTDI provided a simple and 
convenient method in the determination of CT dose and is 
presently the primary concept in CT dose measurement. The 
mathematical description of a CTDI23-28, is shown in Equation 1, 
where   
               CTDI =
1
NT
∫ D(z)d(z)
∞
−∞
                       (1) 
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 D(z) is the dose profile along the scan direction 
 N is the number of tomographic slices acquired 
 T is the slice width  
The CTDI is typically measured using a 100 mm long ionization 
chamber and standardized phantoms that consist of two acrylic 
cylinders that are 15 cm in length, and 16 cm and 32 cm in 
diameter representing the head and body sections of an adult 
respectively28. The CT phantoms and ionization chamber are shown 
in Fig. 7 and Fig. 8 respectively. The CTDI100 represents the 
MSAD dose at the center of a 100 mm scan29. For scan lengths 
greater than 100 mm, the CTDI100 underestimates the MSAD because 
of the exclusion of scatter tails beyond 100 mm range. The 
mathematical description of CTDI10028,29, indicating the 
standardized scan range of 100 mm is shown in Equation 2. The 
CTDI is calculated using Equation 3. 
  
             CTDI100 =
1
NT
∫ D(z)d(z)
50mm
−50mm
                     (2) 
 
           𝐶𝑇𝐷𝐼 =
1
𝑁𝑇
× ?̅? × 𝑁𝑃𝑘𝑙𝑄0 × 𝐾𝑄 × 𝐾𝑇𝑃                     (3) 
Where, 
 KTP is the air density correction factor 
 NPklQ0 is the ionization chamber calibration factor  
 M̅ is the mean dosimeter reading 
 KQ is the beam quality correction factor. 
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2.1.2 Weighted CTDI (CTDIw) 
In general, the radiation dose decreases with depth as it 
penetrates matter through a variety of interactions30. As a 
result, the dose is higher at the surface than in the center28,29. 
In an attempt to address this variation, the weighted CTDI 
(CTDIw) is used in order to determine the average dose across the 
FOV. The CTDIw is mathematically described in Equation 4, where   
 
                CTDIw =
1
3
CTDI  100,center +
2
3
CTDI100,periphery (mGy)           (4) 
 
 CTDI100,center   is the CTDI100 representing the center dose in a 
phantom 
 
 CTDI100,periphery is the CTDI100 representing the surface  dose 
in phantom       
 
 
2.1.3 Volume CT dose index (CTDIvol) 
To accommodate different scan protocols during CT examinations 
and gaps or overlap of dose profiles29, CTDIvol was used. It is 
defined as the ratio of the CTDIw to the scan pitch. It represents 
the dose from a specific scan protocol. Shown in Equation 5 and 
6 are mathematical descriptions of CTDIvol and pitch 
respectively23-29. Theoretically, for a pitch factor of 1, CTDIw 
is equivalent to CTDIvol.  
 
                 CTDIVOL  =  
CTDIW
pitch
  (mGy)                     (5) 
 
                     pitch =  
I
NT
                          (6)
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2.1.4 Dose length product (DLP) 
Patient CT examinations often exceed 100 mm scan length, which 
is used during CTDIw measurements24,28,29. In an attempt to 
accurately estimate the dose from the entire CT examination, the 
CTDIvol is integrated along the actual scan length of the CT 
examination to compute the DLP. The mathematical description of 
the DLP defined by Equation 7.  
 
 
          DLP =  CTDIVOL  ×   scan length (mGy · cm)              (7) 
 
2.2 Dosimetry in kV radiography 
This report follows the methodology of the International Atomic 
Energy Agency (IAEA) Technical Report Series (TRS) number 45728 
to estimate the patient dose by measurement of entrance surface 
air kerma (ESAK).  According to the IAEA TRS 457, patient dose 
in general radiography is determined by three principal 
quantities, incident air kerma (Ki), ESAK and air kerma area 
product (KAP) 28. Kinetic Energy Released in the Medium per unit 
mass (KERMA), represents the amount of energy transferred from 
radiation to matter. Though different from the absorbed dose, 
which represents the amount of energy deposited in matter per 
unit mass, the distinction between the two is negligible for low 
X-ray energies, hence in some literature ESAK is also referred 
to as entrance surface dose (ESD). 
 
2.2.1 Air kerma (Ka), Ki, ESAK and the air KAP 
ESAK is defined as the air kerma on the X–ray beam central axis 
at the patient or phantom surface28. It is typically measured 
using a 20 cm thick water or PMMA phantom with a plane parallel 
plate ionization chamber28.  Similarly to ESAK, Ki is defined as 
the air kerma measured free in air at the position of the patient 
or phantom surface28, excluding backscatter. Air kerma from the 
X-ray machine, at the source to chamber distance (SCD) d, for a 
given exposure settings (kVp and mAs) is calculated using 
Equation 8. 
 
                K(d) = M̅ × NK,Q0  × KQ  × KTP                  (8) 
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Where, 
 M is the mean dosimeter reading collected at SCD.   
 NK,Qo is the calibration factor for the ionization chamber 
 KQ is the beam quality correction factor 
 KTP is the air density correction factor. 
     
The X-ray unit Output Y (d), is calculated as the ratio of the 
air kerma to the tube loading PIt28, as shown in Equation 9. 
 
                        Y(d) = K(d)/PIt                        (9) 
 
Ki is calculated using the relation shown in Equation 10, and 
the inverse square law is applied to derive the air kerma 
incident on the patient 
 
                        Ki  = Y(d) × PIt × (
d
D−t̅̅ ̅̅ ̅̅
)2              (10) 
 
Where,  
 d is source to chamber distance 
 D is the source to table distance 
 t is the thickness of the patient or phantom 
 
 
The relationship between ESAK and Ki is described in Equation 
11. 
 
             ESAK  = Ki  × Backscatter factor (BSF)                               (11) 
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When ESAK measurements are made directly on the 20 cm thick 
Acrylic at a source to chamber distance of 100 cm, the ESAK is 
calculated using Equation 12. 
            ESAK  = M̅  × NK,Q  × KQ  × KTP  ×
BSFW
BSFacrylic
             (12) 
By definition, KAP is air kerma in a plane, integrated over the 
area of interest. It represents the total amount of radiation 
incident on the surface area of the patient or phantom. KAP is 
described in Equation 13, it is the product of the entrance 
surface dose and the exposed area.  
                   KAP =  ESAK × area                     (13) 
2.3 6 MV and Cobalt-60 portal dose 
Radiotherapy linear accelerators (linacs) are typically 
calibrated to deliver a dose rate of 1cGy per monitor unit (MU) 
at a reference depth to, fixed source to calibration distance 
(SCD) and in a reference field size of 10 × 10 cm7. For fixed 
isocentric treatment techniques, the monitor units (MU) required 
to deliver a dose D to the isocenter at depth d is given by 
Equation 147. For linacs that have been calibrated 
isocentrically, SCD is equal to the source to axis distance 
(SAD), which is typically 100 cm and SAD factor is 1. 
 
            MU =
D
 K×TMR(d,rd)×Sc×Sp×SAD factor
                      (14) 
 
Where, 
 K = 1cGy per MU 
 Sc is the collimator scatter factor 
 Sp is the phantom scatter factor 
 TMR is the tissue maximum ratio 
For a given number of monitor units delivered during imaging, 
the dose to the isocentre is similarly defined by Equation 15. 
         D = MU × total Output  Factor(OF)  (cGy)               (15) 
Where the total OF (cGy/MU) is the product of the factors in the 
denominator in Equation 14. The dose from a cobalt-60 therapy 
unit is described by Equation 16. 
 
           D(cGy)  =
Time(min) x Dose rate(cGy /min)
 Output  factor
                    (16) 
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2.4 Estimation of the effective dose 
The imaging dose during radiotherapy is accumulated from a 
variety of imaging techniques. As a result the dose distribution 
resulting from each imaging scenario is different. Because of 
the difference, the direct addition of dose in such instances 
is inappropriate and misleading because of the variation of the 
resulting biological effects associated with each imaging 
scenario15. AAPM TG-7515 recommends that the doses be converted 
to effective dose, which is a quantity that is representative 
of the radiobiological effect, prior to addition or comparison. 
The concept of effective dose was first introduced in 1975 by 
Wolfgang Jacobi 31, defined as “the mean absorbed dose from a 
uniform whole-body irradiation that results in the same total 
radiation detriment as from the non-uniform, partial-body 
irradiation”. The Effective dose cannot be measured directly, 
but is calculated as the sum of the product of equivalent dose 
values to the various exposed organs and their organ weighting 
factors to obtain an equivalent whole body dose. Various 
researchers have published factors that allow for the estimation 
of the effective dose without having to measure organ specific 
doses15,23,32-35. Using such conversion factors, the effective dose 
can be calculated using Equation 1715.  
 
                               E (mSv) = D(mGy) × F(mSv per mGy)                   (17) 
Where,  
 E is the effective dose (mSv) 
 D is the absorbed dose (mGy) 
 F is the semi empirical organ weighting conversion 
factor(mSv per mGy) 
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CHAPTER 3 
3. MATERIALS AND METHODS 
3.1 Imaging Modalities 
This study was conducted at the Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) and Richards Bay Medical Institute 
(RBMI). Dose measurements at CMJAH were carried out on a GE High 
speed NXi CT scanner and a Toshiba LX40 radiotherapy simulator. 
The MV portal dose on a Siemens Primus linac and a Cobalt 
radiotherapy unit was calculated using the tabulated clinical 
beam data based on the electronic records of the portal imaging 
carried out. Dose measurements at RBMI were carried out on a 
Toshiba Aquilion LB CT Scanner, and the Varian On Board Imager 
(OBI) for kV planar imaging and kV cone beam CT.  
3.2 Dosimetry equipment  
3.2.1 CT and CBCT Phantom 
  
 
Fig 7. The two in one head and body acrylic phantom (PTW 
Freiburg, Germany) used for CT and kVCBCT dosimetry at RBMI and 
CT dosimetry at CMJAH is shown. The 16 cm diameter cylinder 
represents the head section and the 32 cm diameter represents 
the body section. Both cylinders are 15 cm in length. The holes 
for the insertion of the ion chamber for measurements of the 
center and peripheral CTDI are indicated by black dots. The 
phantoms have been standardized by the FDA36. 
 
 
 
32 cm diameter 
16 cm diameter 15 cm length 
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3.2.2 CT Ionization chamber 
 
 
Fig. 8. The CT PTW 30009 pencil ionization chamber (PTW Freiburg, 
Germany) with sensitive length of 10 cm is shown. The ion chamber 
calibration factor used during measurements is traceable to 
Bureau International des Poids et Mesures (BIPM) 37. BIPM is the 
international laboratory with the primary role of development 
and maintenance of standards. 
 
3.2.3 Backscatter phantoms for kV dosimetry 
 
Fig. 9. The PTW acrylic and water-equivalent RW3 (PTW Freiburg, 
Germany) slabs are shown. To provide for backscatter, the slabs 
are placed below the ion chamber. The size of each slab is 30 × 
30 cm2, with varying thickness, typically of 1 mm, 2 mm, 5 mm 
and 10 mm.(image copied from ref. 38) 
10 cm length 
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3.2.4 Parallel plate ionization chamber used for kV dosimetry  
 
Fig. 10. The PTW TM77334 parallel plate ionization chamber (PTW       
Freiburg, Germany) is shown. The given calibration factor for 
the ion chamber was traceable to BIPM.  
 
 
3.2.5 Electrometer 
 
 
 
Fig. 11. The PTW 10008 Unidos E electrometer (PTW Freiburg, 
Germany)  used for the measurement of charge during CT,CBCT 
dosimetry and kilovoltage dosimetry on a radiotherapy simulator 
and Varian OBI is shown. (image copied from ref. 39) 
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3.3 Methodology 
3.3.1 CT dosimetry at CMJAH and RBMI 
The CT dosimetry at CMJAH and RBMI was carried out using the 
body and head CT phantoms with a 100 mm PTW 30009 pencil 
ionization chamber connected to a PTW 10008 Unidos E 
electrometer. The center of the phantom was aligned to the 
isocenter of the CT scanner by aligning the phantom etched 
crosshairs to the CT lasers. The measurement setup is shown in 
Fig. 12. Once the setup was completed, a scout scan was acquired 
to check the accuracy of the phantom alignment and to ensure 
that the intended scan length of 100 mm was within the sensitive 
volume of the ionization chamber. The scout scan is shown in 
Fig. 13. The slice thickness of 5 mm, and the scan range of 100 
mm was selected for both body and head measurements.  
 
 
Fig. 12. CT dose measurement setup at (A)-RBMI and (B)-CMJAH is 
shown, indicating the phantom, electrometer and the connecting 
cable from the ion chamber to the electrometer.  
 
The ambient room temperature and pressure were measured prior 
to measurements to enable the correction of the ion chamber 
response in the user’s measurement environment to that of 
calibration. Three electrometer reading were collected in each 
of the five measurement holes in phantom. For each hole 
measurement, the remaining holes were filled with acrylic dummy 
plugs to ensure that the phantom was uniform. The CTDI100 for 
both the center and peripheral positions of the ionization 
chamber was calculated using Equation 3. The acquisition parameters set 
during measurements are shown in table 2. 
A B 
Unidos E electrometer 
GE Hi speed CT  Toshiba Aquilion LB CT  
Ion chamber-electrometer connecting cable 
Body-head phantom 
CT lasers 
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Fig. 13. Scout scan acquired for the verification of the accuracy 
of phantom alignment is shown.  
 
 
 
 
Table 2. CT scan acquisition parameters for the measurement of 
CT dose index using the head and body phantom at CMJAH and RBMI. 
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3.3.2 kVCBCT dosimetry on the Varian OBI 
Measurements were carried out using the head and body CT phantom, 
with the 100 mm ionization chamber connected to the electrometer 
The center of the cylindrical phantom was positioned at the 
isocenter of the linac, by aligning the etched crosshairs on the 
phantom with the room lasers. The collimation of the Y blades 
on the kV source were set to -50 mm and 50 mm such that the 
total collimation in the longitudinal direction was 10 cm at the 
isocenter to conform to the sensitive length of the ionization 
chamber in the center position of the phantom. The accuracy of 
the setup was checked by acquiring a CBCT, shown in Fig. 12. 
Similarly to the CT measurements, three electrometer readings 
were collected in each of the five holes the ion chamber was 
inserted. The set up for measurements is shown in Fig. 13 and 
Fig. 14. Measurements were taken at the kV source to axis 
distance (SAD) of 100 cm, with the kV image detector at a 
distance of 50 cm from the isocentre. 
 
 
Fig. 14. CBCT dose measurement setup is shown. The center phantom was 
aligned to the isocenter of the linac at SAD of 100 cm. 
 
 
 
Isocenter 
kV source 
kV  detector 
100 cm SAD 
CT phantom 
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Fig. 15. Alignment of the phantom using room lasers is shown. 
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Fig. 16. CBCT image acquired for the verification of the phantom 
alignment is shown. On the axial view, the actual isocenter of 
the system is indicated by the intersection of the green and red 
dotted lines, and the setup isocenter is indicated by the ion 
chamber located at the center position of the phantom. The 
alignment is indicated for axial, coronal and sagittal views.
 [-5cm ;5cm] Y 
blades  
Axial view 
Coronal view 
Sagittal view 
System isocenter   
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The measurements were carried out using the Varian OBI imaging 
protocol exposure settings for imaging of the head and pelvic 
section. The exposure settings for head and pelvis imaging 
protocol are indicated in below table. 
 
Table 3. CBCT Scan acquisition parameters for the measurements 
of CBCT dose are indicated. The Y blades were set to the length 
of 10 cm at SAD of 100 cm to conform to the length of the ion 
chamber at the center position of the phantom  
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3.3.3 kV radiography dosimetry on the Varian OBI  
Measurements were carried out using the PTW TM77334 parallel 
plate ionization chamber connected to the electrometer, and 
placed on a water equivalent polystyrene slab phantom to provide 
backscatter. The source to chamber distance was 100 cm. The 
measurement field size was set to 20 × 20 cm2. A fixed field 
size of 20 × 20 cm2 was chosen to estimate patient doses as the 
actual field sizes used during the exam could not be traced from 
the information management system. The setup is shown in figure 
14. Dose Measurements were made using the imaging protocol 
exposure parameters for head and pelvis imaging. The Varian OBI 
half value layer specification (i.e. 70 kVp > 1.5 mm Al and 100 
kVp > 2.7 mm Al) were assumed during measurements. The exposure 
parameters for imaging of the head and pelvis for both anterior-
posterior (AP) and lateral projection are indicated in table 4.  
 
 
Table 4. The exposure parameters for the imaging of the head and 
pelvis are indicated, the same setting were used during 
measurements in a phantom. 
 
  
 
  
  29  
 
 
 
Figure 17. The set up for dosimetry on a kV planar Varian OBI 
is shown. The ion chamber was position at the SCD of 100 cm on 
top of white water phantom. 
 
 
 
 
 
SCD -100 cm 
Ion chamber 
Backscatter 
kV source 
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3.3.4 kV radiography dosimetry on the Toshiba simulator  
Measurements were carried out using a PTW TM77334 parallel plate 
ion chamber connected to the PTW-Freiburg Unidos electrometer. 
The ion chamber was placed on top of a 30 × 30 × 30 cm3 acrylic 
phantom to provide backscatter. The field size was set to 20 × 
20 cm2 at the source to chamber distance (SCD) of 100 cm. The 
ion chamber was positioned such that its entrance window center 
was on the central axis of the X-ray beam. Three electrometer 
readings were collected per measurement exposure settings. The 
room temperature and pressure was measured using the calibrated 
barometer and thermometer prior to measurements. 
 
 
Fig. 18.The setup for measurements of radiographic dose on the 
radiotherapy simulator at CMJAH. 
SCD – 100 cm 
 Acrylic phantom 
Parallel plate Ion chamber 
Simulator gantry 
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3.3.5 Patients imaging data collection procedure 
20 patients who had completed radiation treatment were 
arbitrarily selected from each hospital during the period of 07 
March 2017 to 31 May 2017. The imaging modalities and parameters 
used during planning and IGRT were collected from the electronic 
records. The following data was collected at the hospitals: 
(a) CT (both at CMJAH and RBMI) 
 Number of slices 
 Slice thickness 
 Number of CT examinations 
(B) MV Portal imaging (CMJAH) 
 Monitor units 
 Frequency of imaging 
 Field size 
 Source to skin distance 
 Number of projections 
(c) Toshiba LX40 Simulator (CMJAH) and kV planar imager-Varian 
OBI (RBMI) 
 kVp 
 Exposure(mAs) 
 Field size 
 Focal to skin distance(FSD) 
 Frequency of imaging 
 Number of projections 
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CHAPTER 4 
4. RESULTS AND DISCUSSION 
4.1 In phantom dosimetry results 
4.1.1 CT dose at CMJAH and RBMI 
The CTDI results for the CT scanners used for treatment planning 
at each site are shown in Table 5. 
Quantity 
CMJAH RBMI 
Head Body Head Body 
CTDI
,PMMA,100,C
(mGy) 17.68  12.92 66.89  17.29 
CTDI
,PMMA,100,P
(mGy) 18.12  23.93 78.46  38.89 
CTDI
W 
(mGy) 17.98  ±  1.45 20.26  ±  1.64 74.60  ±  6.19 31.69  ±  2.63 
Pitch factor 1.00 1.00 0.94 0.94 
CTDI
VOL
 (mGy) 17.98  ±  1.45 20.26  ±  1.64 79.53  ±  6.60 33.79  ±  2.80 
Table 5. CTDI results obtained at CMJAH and RMBI are shown. 
Measurements were made using 10 cm pencil type ionization 
chamber with a calibration coefficient traceable to the BIPM and 
an acrylic head and body phantom. The estimated relative 
expanded uncertainty of measurements was 8.1 and 8.3 (with k=2, 
corresponding to 95 % confidence level) for CMJAH and RBMI 
respectively. 
 
 
The computed CTDIvol from CTDI100 measurements were 17.98 ± 1.45 
mGy for the head phantom and 20.26 ± 1.64 mGy for the body 
phantom at CMJAH, and 79.53 ± 6.60 mGy and 33.79 ± 2.80 mGy for 
head and body phantom respectively at RBMI. The average scan 
length from the planning CT at CMJAH was approximately 37 cm, 
whereas the average the scan length at RBMI was approximately 
45 cm. 
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4.1.2 kVCBCT dose at RBMI 
Indicated in table 6 are the kVCBT results measured at RBMI. 
Shown in table 7 is the comparison of kVCBT dose results measured 
by Hyer et al and dose results measured at RBMI. 
Quantity 
RBMI 
Head Body 
CTDI
,PMMA,100,C 
(mGy) 5.31  10.71 
CTDI
,PMMA,100,P
(mGy) 5.14 16.25 
CTDI
W 
(mGy) 5.20 ± 0.43 14.40 ± 1.20 
nCTDIw(mGy/100mAs) 2.00 ± 0.16 1.40 ± 0.11 
Table 6. kVCBCT dose results are shown. The dose was measured 
using the PTW-Freiburg TM77334 ionization chamber and acrylic 
head and body. The Uncertainty of measurements was 8.3, with 
k=2, corresponding to 95 % confidence level 
 
 
 
 Elekta XVI kVCBCT 
Varian OBI  
kVCBCT 
Varian OBI  
kVCBCT 
Quantity Hyer at al. Hyer at al. RBMI 
 Head  Pelvis Head Pelvis Head Pelvis 
n
CTDI
w
 
(mGy/100mAs) 
2.73 1.47 3.57 3.17 1.97 1.36 
CTDI
w
 (mGy) 0.98 ± 0.01 24.13 ± 0.08 5.17 ± 0.03 21.57 ±0.14 5.20 ±0.43 14.40 ± 1.19 
Table 7. Comparison of the weighted and weighted-normalized cone 
beam CDTI values measured by Hyer et al.40 on Elekta XVI and 
Varian OBI systems with the values measured at RBMI using a 16 
cm and 32 cm diameter cylindrical phantom. 
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4.1.3 ESAK measurements on the Varian OBI kV planar imager 
  
Table 8 indicates the ESAK measurements at RBMI on a Varian for 
a fixed field size of 20 × 20 cm2 using the exposure parameter 
settings defined in the imaging protocol of the department. 
Different exposure parameters have been defined for different 
sizes of patients, categorized as small to extra-large 
(approximately 10 cm to 40 cm separation respectively) in order 
to obtain images of optimal quality.  
 
Head 
Projection Applied Voltage (kV) Field size ESAK (mGy) 
AP 85 20 × 20 cm
2
 0.31 ± 0.03 
LAT 65 20 × 20 cm
2
 0.12 ± 0.01 
Pelvis AP   
Size Applied Voltage (kV) Field size ESAK(mGy) 
Small 75 20 × 20 cm
2
 0.16 ± 0.01 
Medium 75 20 × 20 cm
2
 0.21 ± 0.02 
Large 75 20 × 20 cm
2
 0.27 ± 0.02 
Extra large 75 20 × 20 cm
2
 0.33 ± 0.03 
Pelvis lateral  
Size Applied Voltage (kV) Field size ESAK (mGy) 
Small 120 20 × 20 cm
2
 1.49 ± 0.13 
Medium 120 20 × 20 cm
2
 1.49 ± 0.13 
Large 120 20 × 20 cm
2
 3.18 ± 0.27 
Extra large 120 20 × 20 cm
2
 3.18 ± 0.27 
Table 8. The ESAK results for Varian OBI kV planar imager. The 
measurements were made with the field size set to 20 × 20 cm2, 
obtained with a PTW-Freiburg TM77334 parallel ionization chamber 
placed on a phantom at an SCD 0f 100 cm. The uncertainty of 
measurements was approximately 8.5 (with k=2, for 95 % 
confidence level). 
 
 
 
  
 
  
  35  
4.1.4 ESAK on the Toshiba simulator at CMJAH 
Shown in table 9 and 10 are ESAK measurements results obtained 
on the radiotherapy simulator at CMJAH. Table 9 indicates the 
variation of ESAK with voltage (kVp) and exposure (mAs). Table 
10 indicates the ESAK normalized to mAs. The variation is shown 
in figure 16. Table 11 indicates ESAK measures for a fixed field 
size of 20 × 20 cm2 and the exposure setting from the technique 
chart of the department. Similarly to RMBI, patients are 
categorized according to size as “average” to “big” on the 
technique chart with suggested exposure settings for obtaining 
images of acceptable quality. 
 
Applied 
Voltage (kV) 
 
 
ESAK (mGy) 
100 mAs 80 mAs 50 mAs 40 mAs 20 mAs 10 mAs 
50 1.547 1.251 0.728 0.614 0.296 0.136 
60 2.495 2.019 1.248 0.975 0.476 0.227 
70 3.513 2.896 1.751 1.392 0.673 0.314 
80 4.735 3.828 2.373 1.880 0.918 0.448 
90 6.143 4.972 3.099 2.430 1.204 0.647 
100 7.504 5.982 3.752 2.958 1.457 0.728 
Table 9. The ESAK results for the Toshiba radiotherapy simulator 
for a variety of exposure settings. The measurements were made 
with the field size set to 20 × 20 cm2, obtained with a parallel 
ionization chamber placed on a 30 × 30 × 30 cm3 acrylic phantom 
at an SCD of 100 cm. 
 
Applied Voltage (kV) ESAK (mGy/ mAs) 
50 0.015 ± 0.001 
60 0.024 ± 0.002 
70 0.034 ± 0.003 
80 0.047 ± 0.003 
90 0.062 ± 0.005 
100 0.074 ± 0.006 
Table 10. The mean ESAK results, normalized to exposure (mAs) 
setting. The uncertainty of measurements was approximately 8.5 
(with k=2, for 95 % confidence level). 
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Head 
Projection mAs Applied Voltage (kV) Field size ESAK (mGy) 
AP 31.2 60 20 × 20 cm2 0.76 ± 0.07 
LAT 25.0 55 20 × 20 cm2 
 
0.49 ± 0.04 
Pelvis AP 
Size mAs Applied Voltage (kV) Field size ESAK(mGy) 
Average 40.0 63 20 × 20 cm2 1.12 ± 0.09 
Thin 31.2 60 20 × 20 cm2 0.76 ± 0.07 
Big 50.0 70 20 × 20 cm2 1.72 ± 0.15 
Pelvis  lateral 
Size mAs Applied Voltage (kV) Field size ESAK (mGy) 
Average 81.0 80 20 × 20 cm2 3.78 ± 0.32 
Thin 80.0 77 20 × 20 cm2 3.24 ± 0.28 
Big  100.0 96 20 × 20 cm2 7.11 ± 0.60 
Table 11. The ESAK for the imaging protocol at CMJAH is shown. 
The uncertainty of measurements was approximately 8.5 (with k=2, 
for 95 % confidence level). 
 
Fig. 16. A chart of results in table 8, indicating the variation 
of ESAK with mAs and tube potential (kVp) from measurement 
carried out on a Toshiba simulator at CMJAH is shown. The ESAK 
increases with increasing mAs and kVp. The regression 
coefficient of approximately 1, indicated the linear 
relationship between the ESAK and mAs. 
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4.2 Estimation of patient imaging dose at CMJAH 
The dose results indicated in Tables 12-16 represent the imaging 
dose (absorbed dose to the isocentre and ESAK) accumulated from 
acquisition of simulation films, planning CT examinations and 
daily positional verifications on the treatment machine, 
respectively. The patient dose from fluoroscopic screening, 
acquisition of films during a High dose Rate (HDR) brachytherapy 
procedure (if relevant) or other imaging modalities such as 
Positron Emission tomography (PET) and any other diagnostic 
imaging during workup, have not been taken into account in this 
study.  
4.2.1 Planning CT dose  
Patient No. of slices 
Thickness 
(mm) 
No. of CT 
exams 
length (mm) DLP (mGy · cm)  
1 68 5 1 340 688.92 
2 70 5 1 350 709.19 
3 60 5 1 300 607.87 
4 76 5 1 380 683.08 
5 76 5 1 380 769.97 
6 74 5 1 370 665.11 
7 76 5 1 380 769.97 
8 74 5 1 370 665.11 
9 64 5 1 325 658.53 
10 74 5 1 370 665.11 
11 76 5 1 380 769.97 
12 108 3 1 324 582.42 
13 110 3 1 330 593.20 
14 - - - - - 
15 - - - - - 
16 128 3 1 384 778.08 
17 - - - - - 
18 120 3 2 360 1294.26 
19 118 3 2 354 1272.69 
20 167 3 2 501 1801.18 
Table 12. CT dose estimates of patients at CMJAH are shown. The 
total examination dose is presented as the dose length product 
(DLP), which is a product of the CDTIvol and the total scan length 
of the CT examination. Patients 14, 15 and 17 did not have 
planning CTs. 
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4.2.2 MV portal imaging dose to isocentre 
Dual exposures were obtained consisting of a sequence of two 
exposures, with the first exposure being equivalent to the 
treatment field, followed by a larger rectangular field to 
localize the field within the surrounding anatomy. Table 13 
indicates the dose results from first exposure and table 14 is 
the dose from larger open field. Higher monitor units (MU) are 
delivered for larger patients.  
Patient  
number 
AP/PA 
equivalent 
square field 
size 
Output 
factor Depth MU 
AP/PA 
Dose 
Lateral 
equivalent 
square field 
size 
Output 
factor Depth MU 
lateral 
Dose 
 cm mu/cGy cm  cGy cm mu/cGy cm  cGy 
           
1 16 1.26 11.7 4 3.17 16 1.53 16.9 5 2.61 
2 17 1.21 10.7 4 3.31 17 1.21 10.7 5 3.31 
3 17 1.17 9.6 4 3.42 16 1.58 18.0 4 2.53 
4 10 1.03 3.0 4 1.94 15 1.08 6.2 3 1.85 
5 22 1.25 13.2 2 3.20 - - - - - 
 20 1.27 13.2 4 3.15 - - - - - 
6 19 1.14 9.0 4 1.75 19 1.48 16.8 3 1.35 
 15 1.17 9.0 2 1.71 16 1.51 16.8 3 1.32 
7 22 1.04 6.7 2 3.85 - - - - - 
 19 1.06 6.7 4 1.89 - - - - - 
8 18 1.20 10.7 2 1.67 17 1.51 17.2 3 1.32 
9 17 1.16 9.2 2 1.72 16 1.52 17.2 3 1.32 
10 17 1.26 12.0 2 1.59 18 1.47 16.3 3 1.36 
11 17 1.34 13.7 2 1.49 16 1.53 17.3 3 1.31 
12 10 1.12 6.3 3 2.68 10 1.13 6.3 2 2.65 
13 11 0.99 1.9 3 3.03 11 0.99 1.9 2 3.03 
 13 0.98 1.9 3 3.06 - - - -  
14 17 1.18 10.3 3 2.54 15 1.85 21.5 5 2.16 
15 17 1.09 7.3 2 1.83 17 1.40 15.1 3 1.43 
16 10 1.32 10.8 2 1.52 10 1.69 17.0 3 1.18 
17 12 1.25 10.0 3 2.40 12 1.25 10.0 4 2.40 
18  11 1.02 3.2 3 2.94 11 1.01 3.2 2 2.97 
19 15 1.15 8.3 3 2.61 17 1.13 8.7 3 2.65 
20 13 1.47 15.1 2 1.36 13 1.47 15.1 3 1.36 
Table 13. Portal imaging dose delivered to isocentre from the 
treatment field verifications of each patient.   
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Patient  
number 
AP/PA 
equivalent  
square field 
size 
Output 
factor Depth MU 
AP/PA 
Dose 
Lateral 
equivalent 
square field 
size 
Output 
factor Depth MU 
lateral 
Dose 
 cm mu/cGy cm  cGy cm mu/cGy cm  cGy 
           
1 28 1.18 11.7 5 4.24 28 1.38 16.9 5 3.62 
2 29 1.15 10.7 5 4.37 29 1.15 10.7 5 4.35 
3 29 1.12 9.6 5 4.48 29 1.42 18.0 4 2.82 
4 16 0.98 3.0 3 3.06 21 1.04 6.2 3 2.90 
5 26 1.23 13.2 3 2.44 - - - - - 
 24 1.24 13.2 3 2.42 - - - - - 
6 31 1.08 9.0 3 2.79 31 1.35 16.8 3 2.22 
 15 1.17 9.0 3 2.56 16 1.52 16.8 3 1.97 
7 34 1.02 6.7 5 4.90 - - -   
 19 1.07 6.7 3 2.80 - - -   
8 24 1.18 10.7 3 2.54 23 1.42 17.2 3 2.11 
9 23 1.11 9.2 3 2.71 22 1.43 17.2 3 2.10 
10 23 1.22 12.0 3 2.47 24 1.36 16.3 3 2.21 
11 23 1.48 13.7 3 2.03 22 1.43 17.3 3 2.10 
12 20 1.04 6.3 2 1.92 20 1.04 6.3 2 1.92 
13 21 0.95 1.9 2 2.12 21 0.95 1.9 2 2.12 
 13 0.98 1.9 4 4.08 - - - -  
14 29 1.12 10.3  4 3.59 27 1.65 21.5 5 3.04 
15 23 1.05 7.3 3 2.87 23 1.33 15.1 3 2.26 
16 18 1.21 10.8 3 2.48 18 1.49 17.0 3 2.01 
17 24 1.14 10.0 4 3.51 24 1.14 10.0 4 3.51 
18  21 0.97 3.2 2 2.07 21 0.97 3.2 2 2.07 
19 21 1.09 8.3 3 2.76 23 1.11 8.7 3 2.71 
20 19 1.37 15.1 3 2.19 19 1.37 15.1 3 2.19 
Table 14. Portal imaging dose from the second open field exposure 
used for verification.   
 
Table 15 indicates the dose accumulated by patients during the 
complete course of treatment from dual exposures during MV 
portal imaging. The dose was calculated using the tabulated 
output factors for 6 MV, the equivalent square of the 
verification field was calculated in order to interpolate the 
output factor at the depth of interest. The total dose indicated 
was computed as the product of the calculated dose and the 
frequency of imaging. Portal imaging at CMJAH is typically done 
on the first day and half way through treatment, but the actual 
frequency of imaging collected from the Oncology information 
management system.  
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Table 15. The total dose to the isocentre from MV dual exposure 
portal imaging. 
 
 
 
 
 
 
 
 
 
Patient 
number 
No. of AP/PA 
verifications 
N
AP/PA
 
No. of lateral 
verifications 
N
lateral
 
Total dual 
exposure 
dose T
AP/PA
 
Total dual 
exposure dose  
T
lateral
 
T
AP/PA 
+ 
T
lateral
 
Effective 
Dose 
Effective 
Dose 
Total 
effective 
dose 
      AP/PA   Lateral   
T
AP/PA 
+ T
lateral
 
   cGy cGy cGy mSv mSv mSv 
         
1 2 2 14.82 12.48 27.30 9.71 11.00 20.72 
2 2 2 15.35 15.31 30.65 10.05 13.50 23.56 
3 2 2 15.81 10.70 26.50 10.36 9.43 19.79 
4 2 2 10.01 9.50 19.51 1.51 1.44 2.95 
5 2 2 11.18 0.00 11.18 7.32 0.00 7.32 
 1 1 5.57 0.00 5.57 3.65 0.00 3.65 
6 2 2 9.09 7.15 16.24 3.89 2.88 6.78 
 2 2 8.55 6.60 15.14 3.66 2.66 6.32 
7 5 5 43.74 0.00 43.74 28.66 0.00 28.66 
 5 5 23.45 0.00 23.45 15.37 0.00 15.37 
8 3 3 12.63 10.31 22.94 8.27 9.09 17.37 
9 2 2 8.88 6.83 15.71 5.82 6.02 11.84 
10 2 2 8.11 7.13 15.25 5.32 6.29 11.61 
11 3 2 10.58 6.81 17.39 6.93 6.01 12.94 
12 2 2 9.20 9.16 18.36 1.39 1.38 2.78 
13 3 3 15.44 15.44 30.88 2.33 2.33 4.67 
 3  21.43 0.00 21.43 3.24 0.00 3.24 
14 7 3 42.91 15.61 58.51 28.11 13.76 41.88 
15 3 3 14.12 11.05 25.17 9.25 9.75 19.00 
16 13 8 51.93 25.57 77.50 22.25 10.31 32.56 
17 6 6 35.45 35.45 70.91 5.36 5.36 10.72 
18  1 1 5.01 5.04 10.06 0.76 0.76 1.52 
19 2 2 10.75 10.74 21.49 1.62 1.62 3.25 
20 2 2 7.10 7.10 14.20 1.07 1.07 2.15 
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4.2.3 Simulator radiograph Entrance Surface Dose  
The ESAK results measured on the radiotherapy simulator are 
indicated in table 16. The ESAK at the Focus Surface Distance 
(FSD) of each patient was calculated by applying the inverse 
square law to the measured ESAK and multiplied by the frequency 
of imaging.  
 
 
Patient  
number 
Lateral  
FSD (cm) 
No. of 
exams 
Lateral  
ESAK at FSD 
(mGy) 
AP/PA  
FSD (cm) 
No. of 
exams 
AP/PA 
ESAK at FSD 
(mGy) 
       
1 83.1 2 10.96 88.3 2 2.88 
2 89.3 2 9.49 89.3 2 2.82 
3 82.0 2 11.26 90.4 2 2.75 
4 93.2 2 1.13 97.0 2 1.61 
5 -  - 83.2 2 3.25 
6 83.2 2 10.93 91.0 2 2.72 
7 -  - 93.3 2 2.58 
8 82.8 2 11.04 89.2 2 2.83 
9 82.8 2 11.04 89.3 2 2.82 
10 83.7 2 10.80 88.0 2 2.90 
11 82.7 2 11.07 86.3 2 3.02 
12 93.7 2 1.12 93.7 2 1.73 
13 98.1 2 1.02 98.1 2 1.58 
14 78.5 2 12.28 89.7 2 2.79 
15 84.9 2 10.50 92.7 2 2.62 
16 83.0 2 10.99 89.2 2 2.83 
17 90.0 2 1.21 90.0 2 1.88 
18 96.8 2 1.05 96.8 2 1.62 
19 91.3 2 1.18 91.7 2 1.81 
20 84.9 2 1.36 84.9 2 2.11 
    
Table 16. The estimate of ESAK for patients at CMJAH delivered 
during radiographic planar imaging on a radiotherapy simulator 
is shown.  
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4.3 Estimation of the patient imaging dose at RBMI 
The dose results indicated in table 17-19 represent the dose 
from the planning CT examination (DLP), daily positional 
verification on the treatment machine using kVCBCT (DLP) and kV 
portal imaging (ESAK) respectively.  
4.3.1 Planning CT dose  
Patient 
number 
Number 
of slices 
Slice thickness 
(mm) 
 
Scan 
length 
(cm) 
Number 
of CT 
exams 
CTDIVOL 
(mGy) 
DLP (mGy · cm)  
1 134 3 40.2 1 79.53 3197.20  
2 154 3 46.2 1 79.53 3674.40  
3 73 3 21.9 1 79.53 1741.76  
4 80 3 24.0 1 79.53 1908.78  
5 66 3 19.8 1 79.53 1574.74  
6 193 3 57.9 1 79.53 4604.93  
7 154 3 46.2 1 33.79 1561.03  
8 160 3 48.0 1 33.79 1621.85  
9 151 3 45.3 1 33.79 1530.62  
10 147 3 44.1 1 33.79 1490.07  
11 154 3 46.2 1 33.79 1561.03  
12 144 3 43.2 1 33.79 1459.67  
13 162 3 48.6 1 33.79 1642.12  
14 149 3 44.7 1 33.79 1510.35  
15 248 3 74.4 1 33.79 2513.87  
16 143 3 42.9 1 33.79 1449.53  
17 154 3 46.2 1 33.79 1561.03  
18 134 3 40.2 1 33.79 1358.30  
19 185 3 55.5 1 33.79 1875.26  
20 234 3 70.2 1 33.79 2371.96  
        
Table 17. CT dose estimates of patients at RBMI are shown. The 
total dose is indicated by the dose length product (DLP), which 
is a product of the CDTIvol and the total scan length of the 
actual CT examination for each patient. 
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4.3.2 kVCBCT dose  
Patient 
No. 
Scan 
length 
(cm) 
Measured 
CTDI W 
(mGy)
 
 
   
n
CTDI
W
 
(mGy 
/mAs) 
 
Exposure 
( mAs) 
Calculated 
CTDI W 
(mGy) 
DLP 
(mGy·cm) 
No. of 
CBCT 
exams (F) 
DLP x F 
(mGy · cm) 
1 17.6 5.20 0.02 145 2.85 50.12 7 350.84 
2 17.4 5.20 0.02 145 2.85 49.78 5 248.90 
3 17.6 5.20 0.02 145 2.85 50.18 4 200.72 
4 17.6 5.20 0.02 145 2.85 50.29 5 251.45 
5 17.6 5.20 0.02 145 2.85 50.12 7 350.84 
6 17.6 5.20 0.02 145 2.85 50.12 6 300.72 
7 15.9 14.40 0.01 1048 14.29 227.55 6 1365.30 
8 15.8 14.40 0.01 1048 14.29 225.55 5 1127.75 
9 15.7 14.40 0.01 1048 14.29 224.40 5 1122.00 
10 15.8 14.40 0.01 1049 14.31 225.33 7 1577.31 
11 15.9 14.40 0.01 1049 14.31 227.91 6 1367.46 
12 15.8 14.40 0.01 997 13.60 214.57 6 1287.42 
13 15.9 14.40 0.01 1049 14.31 227.48 2 454.96 
14 15.9 14.40 0.01 1048 14.29 227.26 3 681.78 
15 15.7 14.40 0.01 1049 14.31 224.47 2 448.94 
16 15.9 14.40 0.01 1049 14.31 228.05 7 1596.35 
17 15.7 14.40 0.01 1048 14.29 223.83 3 671.49 
18 15.7 14.40 0.01 1046 14.27 224.55 3 673.65 
19 16.2 14.40 0.01 1075 14.66 237.52 6 1425.12 
20 16.0 14.40 0.01 1087 14.83 236.46 7 1655.22 
         
Table 18. kVCBCT dose estimates of patients at RBMI are shown. 
The total dose is presented as the product of dose length product 
(DLP) and the total number of kVCBCT examinations. The DLP was 
calculated as the product of the CDTIvol and the total scan length 
of the CT examination. 
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4.3.3 kV portal imaging Dose  
The ESAK at the FSD of each patient was calculated by applying 
the inverse square law to the measured ESAK assuming a fixed 
field size of 20 × 20 cm2 for all patients. The total ESAK was 
computed as the product of calculated ESAK and the frequency on 
imaging. The kV portal imaging procedure at RBMI consists of a 
single exposure of an open rectangular localization field; dual 
exposures are not carried out. 
Patient 
No. 
Lateral 
FSD (cm) 
No. of 
verifications 
Lateral 
ESAK at FSD 
(mGy) 
AP/PA 
FSD (cm) 
No. of 
verifications 
AP/PA 
ESAK at FSD 
(mGy) 
       
1 83.4 7 1.16 88.2 7 2.79 
2 91.5 5 0.69 91.1 6 2.24 
3 91.8 6 0.82 88.4 6 2.38 
4 87.6 2 0.30 87.4 2 0.81 
5 92.7 7 0.94 90.8 7 2.63 
6 97.9 7 0.85 98.0 7 2.26 
7 83.9 5 22.56 89.7 5 1.69 
8 77.6 4 9.93 89.4 4 1.07 
9 83.7 4 18.13 92.5 4 1.27 
10 80.6 7 16.10 87.4 8 2.23 
11 78.5 4 20.61 87.3 4 1.42 
12 83.4 11 23.63 89.9 10 2.64 
13 80.3 5 24.62 89.3 5 1.34 
14 82.2 4 18.80 88.2 3 1.05 
15 82.8 3 13.90 88.9 3 1.25 
16 83.4 7 31.96 89.8 7 2.36 
17 81.2 3 14.45 80.2 3 1.27 
18 82.1 3 14.13 88.8 3 1.03 
19 68.4 6 40.72 90.5 6 2.41 
20 80.0 7 34.73 86.3 7 3.10 
    
Table 19. The calculated ESAK for kV planar portal imaging for 
both the anterior-posterior and lateral projections is shown.   
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4.4 Estimation of the total effective dose  
The effective dose measurements were computed using equation 13. 
The DLP for both the CT and kVCBCT was converted into the 
effective dose by applying the conversion factors reported in 
table 3 of the AAPM task group 2323. The estimation of effective 
dose from 6 MV portal imaging was calculated using the conversion 
factors determined by Waddington and MacKenzie (their results 
are summarized in table X of the AAPM report Task group 7515). 
Their measurements were made at an SSD of 88 cm for a fixed 
field size of 18 × 15.6 cm2. For the calculation of patient 
effective dose in this report, the inverse square law was applied 
to the results to correct for the difference in the actual 
patient SSD and the SSD used by Waddington and MacKenzie. The 
conversion factors for the estimation of effective dose from x-
ray imaging were determined from JC Le Heron32, as in table 1 
and 2 of the publication. 
 
4.4.1 Patient effective dose at CMJAH   
Table 20-22 indicates the effective dose accumulated by patients 
during the complete course of treatment from MV portal imaging, 
acquisition of simulation films and planning CT examinations 
respectively. The results shown in table 21 do not take into 
account the dose received during fluoroscopic screening but only 
the dose resulting from acquisition of localization images for 
patient set up verification. Indicated in table 23 is the sum 
of total effective doses accumulated from the planning CT, 
simulator and MV portal imaging during the complete course of 
treatment.   
The average effective dose to patients investigated at CMJAH 
from the planning CT, simulator and MV portal imaging for all 
imaging procedures carried out during their complete course of 
treatment was 7.53 ± 0.61 mSv, 0.37 ± 0.03 mSv and 15.53 ± 0.78 
mSv respectively. On average, the effective dose per procedure 
was 7.57 ± 0.61 mSv, 0.19 ± 0.02 mSv and 4.80 ± 0.24 mSv for the 
planning CT, simulation and MV portal imaging respectively.  
For imaging acquired during the complete course of treatment, 
the MV portal imaging dose contribution was the highest. The MV 
portal imaging dose was primarily influenced by the radiation 
beam collimation, and the frequency of imaging.           
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Patient No. 
Total sum of AP/PA and lateral 
dose 
TAP/PA + Tlateral Total effective dose 
  
TAP/PA + Tlateral 
 cGy mSv 
   
1 27.30 20.72 ± 1.05 
2 30.65 23.59 ± 1.18 
3 26.50 19.79 ± 0.99 
4 19.51 2.95 ± 0.15 
5 11.18 10.97 ± 0.55 
6 16.24 13.10 ± 0.64 
7 43.74 44.03 ± 2.20 
8 22.94 17.37 ± 0.87 
9 15.71 11.84 ± 0.59 
10 15.25 11.61 ± 0.58 
11 17.39 12.94 ± 0.65 
12 18.36 2.78 ± 0.14 
13 52.31 7.91 ± 0.40 
14 58.51 41.88 ± 2.09 
15 25.17 19.00 ± 0.95 
16 77.50 32.56 ± 1.63 
17 70.91 10.72 ± 0.54 
18  10.06 1.52 ± 0.08 
19 21.49 3.25 ± 0.16 
20 14.20 2.15 ± 0.11 
   
Average effective 
dose  15.53 ± 0.78 
Table 20. Estimate of the effective dose resulting from 6 MV 
dual exposure verification carried out during the complete 
course of treatment. 
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Patient 
number NAP/PA Nlateral Effective Dose Effective Dose Total effective dose 
   AP/PA   Lateral   
TAP/PA + Tlateral 
   mSv mSv mSv 
1 2 2 0.20 ± 0.02 0.43 ± 0.04 0.63 ± 0.06 
2 2 2 0.20 ±0.02 0.37 ± 0.03 0.57 ± 0.05 
3 2 2 0.19 ±0.02 0.44 ± 0.04 0.63 ± 0.06 
4 2 2 0.01 ±0.00 0.01 ± 0.001 0.02 ± 0.00 
5 2 - 0.23 ±0.02 - 0.23 ± 0.02 
6 2 2 0.19 ±0.02 0.42 ± 0.04 0.61 ± 0.06 
7 2 - 0.18 ±0.02 - 0.18 ± 0.02 
8 2 2 0.20 ± 0.02 0.43 ± 0.04 0.63 ± 0.06 
9 2 2 0.20 ± 0.02 0.43 ± 0.04 0.63 ± 0.06 
10 2 2 0.21 ± 0.02 0.42 ± 0.04 0.63 ± 0.06 
11 2 2 0.21 ± 0.02 0.43 ± 0.04 0.64 ± 0.06 
12 2 2 0.01 ± 0.00 0.01± 0.00 0.02 ± 0.02 
13 2 2 0.01 ± 0.00 0.01 ± 0.00 0.02 ± 0.02 
14 2 2 0.20 ± 0.02 0.48 ± 0.04 0.68 ± 0.06 
15 2 2 0.19 ± 0.02 0.41 ± 0.04 0.6 ± 0.06 
16 2 2 0.20 ± 0.02 0.43 ± 0.04 0.63 ± 0.06 
17 2 2 0.01 ± 0.00 0.01 ± 0.00 0.02 ±0.00 
18 2 2 0.01 ±0.00 0.01 ± 0.00 0.02 ± 0.00 
19 2 2 0.01 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 
20 2 2 0.02 ± 0.00 0.01 ± 0.00 0.03 ± 0.00 
Table 21. Estimate of the effective dose for each patient from 
radiotherapy simulator imaging. 
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Patient No. of slices 
Thickness 
(mm) 
No. of CT 
exams 
length 
(mm) 
DLP (mGy  ·  cm)  
Effective dose 
(mSv) 
1 68 5 1 340 688.92 10.33 ± 0.84 
2 70 5 1 350 709.19 10.64 ± 0.86 
3 60 5 1 300 607.87 9.12 ± 0.74 
4 76 5 1 380 683.08 2.12 ± 0.17 
5 76 5 1 380 769.97 11.55 ± 0.94 
6 74 5 1 370 665.11 9.98 ± 0.81 
7 76 5 1 380 769.97 11.55 ± 0.94 
8 74 5 1 370 665.11 9.98 ± 0.81 
9 64 5 1 325 658.53 9.88 ± 0.80 
10 74 5 1 370 665.11 9.98 ± 0.81 
11 76 5 1 380 769.97 11.55 ± 0.94 
12 108 3 1 324 582.42 1.81 ± 0.15 
13 110 3 1 330 593.20 1.84 ± 0.15 
14 - - - - - - 
15 - - - - - - 
16 128 3 1 384 778.08 11.67 ± 0.95 
17 - - 1 - - - 
18 120 3 2 360 1294.26 4.01 ± 0.32 
19 118 3 2 354 1272.69 3.95 ± 0.32 
20 167 3 2 501 1801.18 5.58 ± 0.45 
Table 22. Estimate of the effective dose for each patient from 
the planning CT. 
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Patient 
number 
CT  effective dose 
(mSv) 
Simulator effective 
dose 
(mSv) 
6 MV portal 
imaging effective 
dose 
(mSv) 
Total  effective dose 
(mSv)                                           
     
1 10.33 ± 0.84 0.63 ± 0.06 20.72 ± 1.04 31.68  ± 1.93 
2 10.64 ± 0.86 0.57 ± 0.05 23.59 ± 1.18 34.77 ± 2.09 
3 9.12 ± 0.74 0.63 ± 0.06 19.79 ± 0.99 29.54 ± 1.78 
4 2.12 ± 0.17 0.02 ± 0.02 2.95 ± 0.15 5.09 ± 0.32 
5 11.55 ± 0.94 0.23 ± 0.02 10.97 ± 0.55 22.75 ± 1.50 
6 9.98 ± 0.81 0.61 ± 0.06 13.10 ± 0.66 23.69 ± 1.52 
7 11.55 ± 0.94 0.18 ± 0.02 44.03 ± 2.20 55.76 ± 3.15 
8 9.98 ± 0.81 0.63 ± 0.06 17.37 ± 0.87 27.98 ± 1.73 
9 9.88 ± 0.80 0.63 ± 0.06 11.84 ± 0.59 22.35 ± 1.45 
10 9.98 ± 0.81 0.63 ± 0.06 11.61 ± 0.58 22.22 ± 1.44 
11 11.55 ± 0.94 0.64 ± 0.06 12.94 ± 0.65 25.13 ± 1.64 
12 1.81 ± 0.15 0.03 ± 0.00 2.78 ± 0.14 4.61 ± 0.29 
13 1.84 ± 0.15 0.03 ± 0.00 7.91 ± 0.40 9.77 ± 0.55 
14 - 0.68 ± 0.06 41.88 ± 2.09 42.56 ± 2.15 
15 - 0.60 ± 0.06 19.00 ± 0.95 19.60 ± 1.00 
16 11.67 ± 0.95 0.63 ± 0.06 32.56 ± 1.63 44.86 ± 2.63 
17 - 0.03 ± 0.00 10.72 ± 0.54 10.74 ± 0.54 
18 4.01 ± 0.32 0.03 ± 0.00 1.52 ± 0.08 5.55 ± 0.40  
19 3.95 ± 0.32 0.03 ± 0.00 3.25 ± 0.16 7.22 ± 0.48 
20 5.58 ± 0.45 0.03 ± 0.00 2.15 ± 0.11 7.76 ± 0.56 
Average 
effective 
dose 
7.53 ± 0.61 0.37 ± 0.03 15.53 ± 0.78 22.68 ± 1.42 
  
Table 23. Total effective dose estimates accumulated at CMJAH 
for each patient during a complete course of treatment resulting 
from the planning CT, simulation and 6 MV portal imaging. 
 
 
4.4.2 Patient effective dose at RBMI  
The results in table 24 represent the total effective dose 
accumulated from the planning CT, and daily positional 
verifications on the linear accelerator using kVCBCT and kV 
planar imaging during the complete course of treatment.  
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Patient 
number 
CT  
effective 
dose 
(mSv) 
kVCBCT 
effective 
dose(mSv) 
kV portal effective dose (mSv) Sum of effective 
doses from all 
modalities (mSv) 
AP/PA Lateral Total effective 
dose 
 
      
1 9.91 ± 0.82 1.09 ± 0.09 0.02 0.01 0.03 ± 0.00 11.03 ± 0.92 
2 11.39 ± 0.95 0.77 ± 0.06 0.01 0.01 0.02 ± 0.00 12.18 ± 1.01 
3 3.66 ± 0.30 0.42 ± 0.03 0.01 0.01 0.02 ± 0.00 4.10 ± 0.34 
4 4.01 ± 0.33 0.53 ± 0.04 0.01 0.00 0.01 ± 0.00 4.55 ± 0.38 
5 3.31 ± 0.27 0.74 ± 0.06 0.02 0.01 0.03 ± 0.00 4.08 ± 0.34 
6 14.28 ± 1.19 0.93 ± 0.08 0.02 0.01 0.03 ± 0.00 15.24 ± 1.26 
7 23.42 ± 1.94 20.48 ± 1.7 1.22 1.19 2.41 ± 0.20 46.31 ± 3.85 
8 24.33 ± 2.02 16.92 ± 1.40 0.47 0.45 0.92 ± 0.08 42.17 ± 3.50 
9 22.96 ± 1.91 16.83 ± 1.40 0.98 0.95 1.93 ± 0.16 41.72 ± 3.47 
10 22.35 ± 1.86 23.66 ± 1.96 0.81 0.78 1.59 ± 0.14 47.60 ± 3.95 
11 23.42 ± 1.94 20.51 ± 1.70 0.98 0.95 1.93 ± 0.16 45.86 ± 3.81 
12 21.89 ± 1.82 19.31 ± 1.60 1.25 1.23 2.48 ± 0.21 43.68 ± 3.63 
13 24.63 ± 2.04 6.82 ± 0.57 1.21 1.19 2.40 ± 0.20 33.85 ± 2.81 
14 22.66 ± 1.88 10.23 ± 0.85 0.98 0.95 1.93 ± 0.16 34.82 ± 2.89 
15 37.71 ± 3.13 6.73 ± 0.56 0.75 0.71 1.46 ± 0.12 45.90 ± 3.81 
16 21.74 ± 1.80 23.95 ± 1.99 1.69 1.66 3.36 ± 0.29 49.05 ± 4.08 
17 23.42 ± 1.94 10.07 ± 0.84 0.74 0.71 1.46 ± 0.12 34.95 ± 2.90 
18 20.37 ± 1.69 10.10 ± 0.84 0.03 0.00 0.03 ± 0.00 31.93 ± 2.53 
19 28.13 ± 2.33 21.38 ± 1.77 1.46 1.43 2.89 ± 0.25 52.40 ± 4.25 
20 35.58 ± 2.95 24.83 ± 2.06 1.70 1.66 3.36 ± 0.29 63.77 ± 5.30 
Average 
effective 
dose 
19.96 ± 1.66 11.82 ± 0.98 
 
1.49 ± 0.12 33.26 ± 2.76 
Table 24. Total effective dose estimation to patients at RBMI 
from the planning CT, and kVCBCT and kV portal imaging 
accumulated during the complete course of treatment. 
 
Accumulated effective dose from other imaging modalities such 
as PET scans used for image fusion, are not taken into account. 
The average effective dose from the planning CT, kVCBCT and kV 
portal imaging for all imaging procedures carried out during the 
complete course of treatment was 19.96 ± 1.66 mSv, 11.81 ± 0.98 
mSv and 1.49 ± 0.12 mSv  respectively. The kV portal imaging 
dose measured at RBMI ranged from 0.1 to 3.2 mGy. The greatest 
contribution to the total effective dose from imaging alone 
originated from the planning CT scan.   
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5. CONCLUSION 
The results indicate that considerable dose could be delivered 
to patients during image guided radiotherapy, primarily when 
imaging procedures are over utilized and not optimized, adding 
more burden of dose to the already high levels of dose they 
receive from their treatment. The dose contribution from the 
planning CT was the highest in this study and was primarily 
influenced by the scan length. This can be reduced if scans are 
not acquired significantly beyond the ROI required for planning 
purposes. However, insufficient scan lengths may not provide 
sufficient image information required for radiation therapy 
planning.  
Modern imaging techniques such as kVCBCT applied during patient 
setup verification, can also add a significant dose when over 
utilized.  
In comparison with MV portal imaging dose, kV portal imaging 
dose is less and in some instances, more useful image quality 
can be obtained compared to MV imaging.  The ability to simply 
subtract the MV portal imaging dose from the prescribed dose 
when imaging actual treatment ports should be considered when a 
large number of verifications are requested.   
Imaging dose in IGRT should consider the ALARA principle without 
compromising the image quality and information required to 
achieve the objectives of IGRT. This requires optimization of 
beam collimation, exposure parameters for both types of portal 
imaging, as well as the prescribed frequency of imaging and the 
scan lengths for CT exams.  
It is recommended that radiotherapy institutions examine the 
effective dose to patients from their IGRT modalities and adapt 
their imaging protocols accordingly. Given that CT doses were 
found to be the highest, it is highly recommended that 
institutions considering daily CBCT imaging and emerging 
advanced techniques using 4-dimensional CT for instance, pay due 
attention to the additional dose burden to patients.    
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